Galapagos NV ADR (GLPG)

Jan 8, 2025, 1:30 AM EST - 10 days ago

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Jan 7, 2025, 4:01 PM EST - 10 days ago

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 7, 2024, 12:30 PM EST - 5 weeks ago

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Nov 5, 2024, 4:01 PM EST - 2 months ago

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Oct 31, 2024, 3:50 PM EDT - 2 months ago

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 2 months ago

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 7, 2024, 1:00 AM EDT - 3 months ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Oct 1, 2024, 6:00 AM EDT - 3 months ago

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Sep 30, 2024, 4:01 PM EDT - 3 months ago

Galapagos receives transparency notification from EcoR1 Capital

Sep 3, 2024, 4:01 PM EDT - 4 months ago

Galapagos receives transparency notification from FMR LLC

Aug 23, 2024, 3:49 PM EDT - 5 months ago

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Aug 23, 2024, 1:00 AM EDT - 5 months ago

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Aug 2, 2024, 1:25 PM EDT - 6 months ago

Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 6 months ago

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Aug 1, 2024, 4:01 PM EDT - 6 months ago

Galapagos reports half-year 2024 financial results and provides second quarter business update

Jun 14, 2024, 4:01 PM EDT - 7 months ago

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

May 30, 2024, 4:01 PM EDT - 8 months ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

ADAP

May 30, 2024, 4:01 PM EDT - 8 months ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

ADAP

May 16, 2024, 4:01 PM EDT - 8 months ago

Galapagos creates new subscription right plans

May 15, 2024, 4:01 PM EDT - 8 months ago

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

May 4, 2024, 11:51 AM EDT - 9 months ago

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:01 PM EDT - 9 months ago

Galapagos reports first quarter 2024 financial results

Apr 30, 2024, 4:01 PM EDT - 9 months ago

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Apr 4, 2024, 4:01 PM EDT - 10 months ago

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Mar 28, 2024, 4:01 PM EDT - 10 months ago

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

Mar 26, 2024, 4:01 PM EDT - 10 months ago

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Mar 7, 2024, 11:30 AM EST - 11 months ago

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Feb 23, 2024, 10:23 AM EST - 11 months ago

Galapagos NV (GLPG) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:01 PM EST - 11 months ago

Galapagos announces full year 2023 results and outlook for 2024

Feb 15, 2024, 4:01 PM EST - 1 year ago

Galapagos presents at EBMT-EHA annual meeting 2024

Jan 31, 2024, 4:01 PM EST - 1 year ago

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Jan 4, 2024, 4:01 PM EST - 1 year ago

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

TMO

Jan 3, 2024, 4:01 PM EST - 1 year ago

BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

Jan 3, 2024, 4:01 PM EST - 1 year ago

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Jan 2, 2024, 1:00 AM EST - 1 year ago

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Dec 19, 2023, 4:01 PM EST - 1 year ago

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Dec 9, 2023, 12:00 PM EST - 1 year ago

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Dec 7, 2023, 4:01 PM EST - 1 year ago

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Nov 6, 2023, 7:45 AM EST - 1 year ago

Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

Nov 5, 2023, 9:14 AM EST - 1 year ago

Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:01 PM EDT - 1 year ago

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Oct 30, 2023, 4:01 PM EDT - 1 year ago

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Sep 19, 2023, 4:01 PM EDT - 1 year ago

Galapagos appoints Simon Sturge to its Board of Directors

Aug 28, 2023, 4:01 PM EDT - 1 year ago

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Aug 4, 2023, 4:30 PM EDT - 1 year ago

Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 4:01 PM EDT - 1 year ago

Galapagos announces first half-year 2023 financial results

Jun 15, 2023, 4:01 PM EDT - 1 year ago

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

Jun 12, 2023, 4:01 PM EDT - 1 year ago

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

INCY

Jun 5, 2023, 4:01 PM EDT - 1 year ago

Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

May 23, 2023, 4:01 PM EDT - 1 year ago

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis